ライフサイエンスコーパス: peritoneal dialysis

1 were on dialysis (73.6% hemodialysis; 26.4% peritoneal dialysis).

2 en and 378 in women on continuous ambulatory peritoneal dialysis).

3 itonitis compared with conventional fluid in peritoneal dialysis.

4 in an adolescent patient with HIV receiving peritoneal dialysis.

5 in very young children treated with chronic peritoneal dialysis.

6 nts received hemodialysis and fewer received peritoneal dialysis.

7 eers, 25 patients on hemodialysis, and 20 on peritoneal dialysis.

8 individuals undergoing continuous ambulatory peritoneal dialysis.

9 t propensity of being initially treated with peritoneal dialysis.

10 dergoing maintenance hemodialysis or chronic peritoneal dialysis.

11 Infection is the Achilles heel of peritoneal dialysis.

12 atients more information about the option of peritoneal dialysis.

13 eration in choosing between hemodialysis and peritoneal dialysis.

14 ialysis and 41 were on continuous ambulatory peritoneal dialysis.

15 less removed from the patient during routine peritoneal dialysis.

16 adaveric renal transplants after a period of peritoneal dialysis.

17 biocompatible dialysis fluids, and automated peritoneal dialysis.

18 nal failure treated by continuous ambulatory peritoneal dialysis.

19 tients with chronic renal failure treated by peritoneal dialysis.

20 in patients undergoing continuous ambulatory peritoneal dialysis.

21 gle transport organ for small solutes during peritoneal dialysis.

22 ter transfer to hemodialysis or intermittent peritoneal dialysis.

23 potential to reduce costs of ESKD care with peritoneal dialysis.

24 sis, with the remaining 150 (6.4%) receiving peritoneal dialysis.

25 eiving hemodialysis than for those receiving peritoneal dialysis.

26 are available from interventional studies in peritoneal dialysis.

27 rrhosis, indwelling catheters, or undergoing peritoneal dialysis.

28 al infection, but resulted in fibrosis after peritoneal dialysis.

29 uals with end-stage kidney disease receiving peritoneal dialysis.

30 ifficile peritonitis in a patient undergoing peritoneal dialysis.

31 blem in the treatment of kidney failure with peritoneal dialysis.

32 olic control in diabetic patients undergoing peritoneal dialysis.

33 F) and is a complicating factor in long-term peritoneal dialysis.

34 ults may not be generalizable to patients on peritoneal dialysis.

35 a substantial role in ultrafiltration during peritoneal dialysis.

36 KT 65.8%-52.6%, hemodialysis 92.6-81.5%, and peritoneal dialysis 100%-90%), whereas 100% of healthy c

37 tion provided (average of information items: peritoneal dialysis [69% excellent] vs hemodialysis [30%

38 dextrose during the long dwell of automated peritoneal dialysis, a multicenter, randomized, double-b

39 15% of the prevalent patients are treated by peritoneal dialysis across the country.

40 undation-Dialysis Outcome Quality Initiative Peritoneal Dialysis Adequacy Clinical Practice Guideline

41 undation-Dialysis Outcome Quality Initiative Peritoneal Dialysis Adequacy Work Group recommended that

42 urinary oxalate values than those receiving peritoneal dialysis alone.

43 thesis that in patients undergoing automated peritoneal dialysis, an arterial pH of 7.43-7.45, as com

44 Twenty-five percent of patients undergoing peritoneal dialysis and 5% of hemodialysis patients swit

45 ke in patients who are receiving maintenance peritoneal dialysis and have evidence of malnutrition.

46 lysis did not reduce the differences between peritoneal dialysis and hemodialysis patients.

47 define "adequate" dialysis for the pediatric peritoneal dialysis and hemodialysis populations have no

48 We expect mortality rates for both peritoneal dialysis and hemodialysis to fall, however, a

49 ssues: (1) What are the equivalent doses for peritoneal dialysis and hemodialysis? (2) Are dialytic a

50 children receiving dialysis are treated with peritoneal dialysis and pediatric nephrologists report i

51 fter 7 years on hemodialysis, was changed to peritoneal dialysis and subsequently suffered two stroke

52 case of T. inkin peritonitis associated with peritoneal dialysis and the first to be treated with cas

53 h did not differ between patients undergoing peritoneal dialysis and those undergoing hemodialysis du

54 was grouped into dialysis (hemodialysis and peritoneal dialysis) and nondialysis patients and into w

55 c renal replacement therapy (hemodialysis or peritoneal dialysis), and missing peak plasma creatinine

56 ysis (hemodialysis and continuous ambulatory peritoneal dialysis), and transplantation.

57 1) for haemodialysis, 1.4 pmp to 1.6 pmp for peritoneal dialysis, and 0.43 pmp to 0.46 pmp for kidney

58 Two of the study's 59 patients were on peritoneal dialysis, and 57 were on hemodialysis.

59 lities, including conventional hemodialysis, peritoneal dialysis, and both continuous venovenous and

60 ge >65 years, white race, dialysis duration, peritoneal dialysis, and congestive heart failure, but n

61 om CKD rabbits, patients on hemodialysis and peritoneal dialysis, and HNE-modified HDL.

62 hemodialysis (either in-center or at home), peritoneal dialysis, and kidney transplant.

63 ) countries had facilities for hemodialysis, peritoneal dialysis, and kidney transplantation, respect

64 s in Africa had facilities for hemodialysis, peritoneal dialysis, and kidney transplantation, respect

65 complication for surgery patients, those on peritoneal dialysis, and the critically ill.

66 Hemodialysis, peritoneal dialysis, and transplantation services were f

67 h the Dubois formula used to estimate BSA in peritoneal dialysis; and (2) comparison of percent devia

68 Automated peritoneal dialysis (APD) had a higher carbon impact tha

69 asibility and clinical outcomes of automated peritoneal dialysis (APD) in anuric patients.

70 The prevalence of patients on automated peritoneal dialysis (APD) is increasing worldwide and ma

71 f economic evaluation information, automated peritoneal dialysis (APD) is not included in Thailand's

72 In conclusion, compared with HD, peritoneal dialysis appears to be associated with higher

73 Although the mortality rate for peritoneal dialysis appears to be higher than that for h

74 In a mouse model of peritoneal dialysis, AqF026 enhanced the osmotic transpo

75 Removers remove excess fluid through peritoneal dialysis, aquaphoresis, or hemodialysis.

76 e hypothesis that mass transfer rates during peritoneal dialysis are dependent on the area of periton

77 Patients on haemodialysis or peritoneal dialysis are likely to be at increased risk o

78 r hemodialysis and the various modalities of peritoneal dialysis are reviewed in light of the state o

79 Automated forms of peritoneal dialysis are used by the majority of children

80 ld be expected to increase the efficiency of peritoneal dialysis, are not available.

81 Hemodialysis (compared with peritoneal dialysis) as initial therapy and starting dia

82 ildren in 18 countries who commenced chronic peritoneal dialysis at <24 months of age.

83 (mean age, 9.9 +/- 5.6 yr) receiving chronic peritoneal dialysis at 14 centers.

84 LE cadaveric transplant recipients receiving peritoneal dialysis before transplant compared with cont

85 ng maintenance dialysis (ie, hemodialysis or peritoneal dialysis) between April 1, 2010, and March 31

86 bolic indices in diabetic patients receiving peritoneal dialysis but may be associated with an increa

87 Peritonitis is a major complication of peritoneal dialysis, but the relationship between perito

88 fore the initiation of continuous ambulatory peritoneal dialysis (CAPD) and 2 wk after starting the t

89 ritonitis complicating continuous ambulatory peritoneal dialysis (CAPD), a causative organism is neve

90 d, in subjects undergoing chronic ambulatory peritoneal dialysis (CAPD), and in control subjects.

91 ribe the first case of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis due to La

92 her carbon impact than continuous ambulatory peritoneal dialysis (CAPD).

93 NSP occurred frequently after peritoneal dialysis catheter placement (prevalence 10% t

94 cular catheters, cerebrospinal fluid shunts, peritoneal dialysis catheters, and prosthetic joints.

95 Continuous flow peritoneal dialysis (CFPD) was instituted after percutan

96 w levels of glucose degradation products for peritoneal dialysis compared with standard solutions are

97 idney replacement therapies (KRTs, including peritoneal dialysis, continuous KRT, haemodialysis and h

98 tional status in children undergoing chronic peritoneal dialysis (CPD) around the globe.

99 was studied in 68 randomly selected chronic peritoneal dialysis (CPD) patients.

100 4.0 percentage points and the access gap to peritoneal dialysis decreased by 3.8 percentage points i

101 e kidney was transplanted into a 61-year-old peritoneal dialysis dependent without complication.

102 Patients with ESRD undergoing peritoneal dialysis develop progressive peritoneal fibro

103 ortion of all dialysis patients treated with peritoneal dialysis did not change in developing countri

104 ? and (3) Will survival improve by providing peritoneal dialysis doses above those currently recommen

105 n by peritoneal leukocytes isolated from the peritoneal dialysis effluent (PDE) of noninfected uremic

106 l specimens such as whole blood, plasma, and peritoneal dialysis effluent with clinically relevant de

107 dialysis patients (734 hemodialysis and 271 peritoneal dialysis) enrolled between October 1995 and J

108 Because so much evidence from the collective peritoneal dialysis experience suggested that a weekly K

109 ng heat-inactivated D39 (HI-D39) and sterile peritoneal dialysis fluid (PDF), we investigated whether

110 ll survival during exposure to glucose-based peritoneal dialysis fluid (PDF).

111 nd that endogenously generated OxPL in human peritoneal dialysis fluid from end-stage renal failure p

112 ens except for tissue, continuous ambulatory peritoneal dialysis fluid, and CSF from patients with sh

113 Data from 14 patients undergoing peritoneal dialysis for end-stage renal disease but with

114 y in humans undergoing continuous ambulatory peritoneal dialysis for end-stage renal disease.

115 likely than adult nephrologists to recommend peritoneal dialysis for identical patients (odds ratio,

116 rgoing long-term dialysis (8 hemodialysis; 1 peritoneal dialysis) for ESRD of diverse etiologies.

117 SA) in 301 patients on continuous ambulatory peritoneal dialysis (four daily exchanges with 2-L excha

118 e assessed longitudinal trends in the use of peritoneal dialysis from 1997 to 2008 in 130 countries.

119 However, long-term peritoneal dialysis (>8 years) is limited to a small per

120 tal stroke is greater on hemodialysis versus peritoneal dialysis has not been systematically examined

121 Peritoneal dialysis has now become an established form o

122 omes in patients undergoing hemodialysis and peritoneal dialysis have improved, and current research

123 patients, studies in CKD patients undergoing peritoneal dialysis have yielded mixed results.

124 No patients undergoing peritoneal dialysis, hemodialysis, or nondialysis who ex

125 lable in 162 (98%) of 165 countries, chronic peritoneal dialysis in 130 (79%), and kidney transplanta

126 , we included the 1316 patients who received peritoneal dialysis in Australia and New Zealand from Ma

127 morbidity which ultimately limit the use of peritoneal dialysis in end-stage renal failure.

128 ement therapy, the bioartificial kidney, and peritoneal dialysis in the management of this complicate

129 significantly higher among those undergoing peritoneal dialysis in the second year (relative hazard,

130 o haemodialysis in 12 (19%) of 62 countries, peritoneal dialysis in three (6%) countries, or kidney t

131 The use of automated peritoneal dialysis increased by 14.5% in developing cou

132 s in large subjects on continuous ambulatory peritoneal dialysis is a low normalized drain volume.

133 Peritoneal dialysis is an important dialysis modality an

134 he use of a gene therapy strategy to enhance peritoneal dialysis is an innovative and exciting concep

135 though there is a perception that the use of peritoneal dialysis is declining worldwide, compilations

136 D patient treated with continuous ambulatory peritoneal dialysis is described.

137 Reimbursement for peritoneal dialysis is lower in most countries except Ge

138 in a patient receiving continuous ambulatory peritoneal dialysis is presented.

139 Convective solute transport during peritoneal dialysis is proportional to the transperitone

140 t pathways that govern solute removal during peritoneal dialysis is reviewed.

141 Peritoneal dialysis is the major renal replacement thera

142 Peritoneal dialysis is the renal replacement therapy of

143 While peritoneal dialysis is used in less than 17% of adults w

144 Liposome-supported peritoneal dialysis (LSPD) with transmembrane pH-gradien

145 These data suggest that increased use of peritoneal dialysis may benefit incident ESRD patients.

146 Our results suggest that peritoneal dialysis may represent a simple and effective

147 ing in the home through home hemodialysis or peritoneal dialysis, may lead to improvement in several

148 Patients studied (hemodialysis, n = 121,970; peritoneal dialysis, n = 7129) began dialysis between 19

149 In peritoneal dialysis, new solutions using icodextrin may

150 Patients who undergo peritoneal dialysis often develop peritoneal fibrosis th

151 ional investigation for applications such as peritoneal dialysis or clinical situations associated wi

152 ificant intermethod difference by condition (peritoneal dialysis or control).

153 ified AMI patients who were receiving either peritoneal dialysis or hemodialysis before admission.

154 r who cannot undergo transplantation, either peritoneal dialysis or hemodialysis may be chosen.

155 A general assumption in peritoneal dialysis or intraperitoneal chemotherapy has

156 ay be useful in intraperitoneal therapies of peritoneal dialysis or intraperitoneal chemotherapy.

157 004 through December 2009 and either died on peritoneal dialysis or within 30 days of transfer to hem

158 stigation are paracentesis, ultrafiltration, peritoneal dialysis, oral sodium binders, vasodilator th

159 ed by treatment modality-hemodialysis versus peritoneal dialysis (P<0.001 for interaction)-and was st

160 h 1.3% (95% CI, 0.5% to 2.4%) of patients on peritoneal dialysis (P=0.01), and that a statistically s

161 ropoietin doses plateaued at 30,000 units in peritoneal dialysis patients and 60,000 units in hemodia

162 tin plateaued at 3 mo in both groups: 25% in peritoneal dialysis patients and 80% in hemodialysis pat

163 Continuous ambulatory peritoneal dialysis patients are able to increase albumi

164 ons of mortality in matched hemodialysis and peritoneal dialysis patients are lacking.

165 ompare survival of incident hemodialysis and peritoneal dialysis patients by intention-to-treat analy

166 analyzed data from incident hemodialysis and peritoneal dialysis patients in 2009 who were at least 6

167 ith a 2.5-fold increase in the prevalence of peritoneal dialysis patients in developing countries.

168 month-by-month basis) U.S. hemodialysis and peritoneal dialysis patients in terms of the proportion

169 A total of 1,730 peritoneal dialysis patients in the CRC for ESRD prospec

170 Over 12 years, the number of peritoneal dialysis patients increased in developing cou

171 yzing local and systemic immune responses in peritoneal dialysis patients presenting with acute bacte

172 Thus, use of glucose-sparing regimens in peritoneal dialysis patients should be accompanied by cl

173 om day 0, cumulative survival was higher for peritoneal dialysis patients than for hemodialysis patie

174 se to excess cases of aseptic peritonitis in peritoneal dialysis patients using icodextrin-containing

175 e aim to assess mortality risk prediction in peritoneal dialysis patients using machine-learning algo

176 Excess cases of aseptic peritonitis in peritoneal dialysis patients were due to peptidoglycan c

177 O3) and sevelamer were compared in pediatric peritoneal dialysis patients with bone biopsy-proven 2 d

178 If peritoneal dialysis patients with high mCCI (>4) were ag

179 Nine peritoneal dialysis patients with mild to moderate malnu

180 ial, we randomly assigned 185 incident adult peritoneal dialysis patients with residual renal functio

181 Adult Medicare-insured hemodialysis and peritoneal dialysis patients without a history of stroke

182 In 2008, there were approximately 196,000 peritoneal dialysis patients worldwide, representing 11%

183 study suggests that in most stable automated peritoneal dialysis patients, a mean arterial pH of 7.44

184 roke in large numbers of hemodialysis versus peritoneal dialysis patients, are reviewed.

185 ng a time of improving outcomes for incident peritoneal dialysis patients, measured as reduced hazard

186 In peritoneal dialysis patients, rates rose from 5.7 in 199

187 Among the 620 peritoneal dialysis patients, stroke rates were slightly

188 es performed in actual continuous ambulatory peritoneal dialysis patients, the difference between del

189 s significantly associates with mortality in peritoneal dialysis patients.

190 notable risk factors for mortality in Korean peritoneal dialysis patients.

191 red following intravenous bolus in 11 stable peritoneal dialysis patients.

192 composition can be readily applied to stable peritoneal dialysis patients.

193 body-composition methods in 30 well-dialyzed peritoneal dialysis patients.

194 t method of evaluating nutritional status in peritoneal dialysis patients.

195 ether the measurement was made on control or peritoneal dialysis patients.

196 itoneal membranes of 130 patients undergoing peritoneal dialysis (PD) and compared them with the feat

197 registry studies comparing mortality between peritoneal dialysis (PD) and hemodialysis (HD) patients

198 f life (HRQOL) between hemodialysis (HD) and peritoneal dialysis (PD) are not clearly known.

199 s (EPS) is a rare but severe complication of peritoneal dialysis (PD) characterized by extensive fibr

200 It is unclear whether peritoneal dialysis (PD) compared with hemodialysis (HD)

201 Us/mL in phosphate buffered saline (PBS) and peritoneal dialysis (PD) fluid.

202 Heat sterilization of peritoneal dialysis (PD) fluids leads to partial degrada

203 Many programs have adopted the use of peritoneal dialysis (PD) for fluid management; however,

204 l technical and nontechnical improvements in peritoneal dialysis (PD) have occurred during recent yea

205 te men, and white women who initiated HD and peritoneal dialysis (PD) in the Dialysis Morbidity and M

206 ite mupirocin prevents Staphylococcus aureus peritoneal dialysis (PD) infections but does not reduce

207 Peritoneal dialysis (PD) is a life-saving form of renal

208 Fungal peritonitis in a patient on peritoneal dialysis (PD) is a refractory injury accompan

209 Acute peritoneal dialysis (PD) is an important low-cost treatm

210 l may influence the decision for the initial peritoneal dialysis (PD) modality is unknown.

211 uated the effect of hemodialysis (HD) versus peritoneal dialysis (PD) on the incidence of postoperati

212 Few studies in patients undergoing either peritoneal dialysis (PD) or hemodialysis (HD) have asses

213 ge renal disease (ESRD) maintained either on peritoneal dialysis (PD) or hemodialysis (HD).

214 Home dialysis, which comprises peritoneal dialysis (PD) or home hemodialysis (home HD),

215 In multivariate analyses, the selection of peritoneal dialysis (PD) over hemodialysis (HD) was sign

216 2-month period from the dialysis fluid of a peritoneal dialysis (PD) patient who experienced recurre

217 nts (pediatric n = 1469; adult n = 305,323); peritoneal dialysis (PD) patients (pediatric n=982; adul

218 from the blood of 20 haemodialysis (HD), 17 peritoneal dialysis (PD) patients and 20 matched control

219 afety of cinacalcet in hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH > or =300 pg/

220 ion episodes, and causes of graft failure in peritoneal dialysis (PD) patients with those maintained

221 In peritoneal dialysis (PD) patients, oral iron therapy is

222 Mortality remains high in peritoneal dialysis (PD) patients.

223 Effects of the initial peritoneal dialysis (PD) prescription on clinical outcom

224 Peritoneal dialysis (PD) remains limited by dialysis fai

225 ucosone-3-ene (3,4-DGE), which is present in peritoneal dialysis (PD) solutions after heat sterilizat

226 participants with end-stage renal disease on peritoneal dialysis (PD) underwent randomization and cro

227 gement in 1394 pediatric patients undergoing peritoneal dialysis (PD) who were prospectively followed

228 in patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) with those in healthy controls.

229 rospectively analyzed 65 patients undergoing peritoneal dialysis (PD) without prior cardiovascular di

230 peritoneal membrane in patients treated with peritoneal dialysis (PD), but the underlying mechanisms

231 In patients undergoing peritoneal dialysis (PD), chronic exposure to nonphysiol

232 complication in patients undergoing chronic peritoneal dialysis (PD), limiting the duration of PD as

233 Technical innovations in peritoneal dialysis (PD), now used widely for the long-t

234 For patients on peritoneal dialysis (PD), the estimate is critical when

235 on peritoneal tissues in patients treated by peritoneal dialysis (PD), yet plasma levels of the AGE p

236 f 52 adult patients during episodes of acute peritoneal dialysis (PD)-associated peritonitis by multi

237 Early peritoneal dialysis (PD)-related infection is a severe c

238 intermittent dosing of antibiotics to treat peritoneal dialysis (PD)-related peritonitis.

239 wed pretransplant hemodialysis (HD), and 34% peritoneal dialysis (PD).

240 itical component of dialysis prescription in peritoneal dialysis (PD).

241 arting treatment on hemodialysis (HD) versus peritoneal dialysis (PD).

242 ts with end stage kidney failure who receive peritoneal dialysis (PD).

243 g that limits ultrafiltration in patients on peritoneal dialysis (PD).

244 mains the main cause of technique failure in peritoneal dialysis (PD).

245 se of morbidity and mortality during chronic peritoneal dialysis (PD).

246 tients with CKD and is further aggravated by peritoneal dialysis (PD).

247 l) patients incident to hemodialysis (HD) or peritoneal dialysis (PD).

248 neal membrane becomes damaged in patients on peritoneal dialysis (PD).

249 ts on hemodialysis [HD] and nine patients on peritoneal dialysis [PD]) and 41 healthy control subject

250 ialysis patients (both hemodialysis [HD] and peritoneal dialysis [PD]), complete financial records (a

251 In children who are on chronic peritoneal dialysis, peritonitis is the primary complica

252 haemodialysis for inherent complications of peritoneal dialysis--peritonitis, peritoneal access, ina

253 Those who received combined hemodialysis and peritoneal dialysis pretransplant had lower posttranspla

254 s of initiating dialysis, patients receiving peritoneal dialysis rated their care higher than those r

255 tracranial hemorrhage should be treated with peritoneal dialysis rather than hemodialysis.

256 especially among elderly diabetic patients, peritoneal dialysis remains an acceptable therapy for th

257 /-8 and 1.5+/-0.9 years (34 hemodialysis, 16 peritoneal dialysis), respectively.

258 and 89.1% and 10.8% were on hemodialysis and peritoneal dialysis, respectively.

259 compared with satellite CvHD, home CvHD, and peritoneal dialysis, respectively.

260 d in pediatric patients with continuous flow peritoneal dialysis, resulting in a significant improvem

261 summary, the number of patients treated with peritoneal dialysis rose worldwide from 1997 to 2008, wi

262 Moreover, in patients with kidney failure, peritoneal dialysis significantly decreased glutamate co

263 th adjusted hazards for death or transfer to peritoneal dialysis slightly worsened or were unchanged

264 es and consequences in patients treated with peritoneal dialysis, so their prevention may require dif

265 Conventional peritoneal dialysis solutions (PDS) are vasoactive.

266 Glucose-containing peritoneal dialysis solutions may exacerbate metabolic a

267 the major vasoactive components of clinical peritoneal dialysis solutions.

268 Peritoneal dialysis starters had a 16% higher rate of de

269 Therefore, the decline in peritoneal dialysis take-on cannot be entirely explained

270 In the United States, chronic peritoneal dialysis take-on has declined among incident

271 patients in the United States, we found that peritoneal dialysis take-on significantly decreased from

272 k after dialysis initiation was 8% lower for peritoneal dialysis than for matched hemodialysis patien

273 The average sensitivity was 0.10 greater in peritoneal dialysis than hemodialysis patients.

274 Also, more patients undergoing peritoneal dialysis than hemodialysis switched type of d

275 elihood of pregnancy was seen among women on peritoneal dialysis than on hemodialysis (HR, 0.47; 95%

276 It is becoming clear that during peritoneal dialysis, the peritoneal membrane undergoes v

277 ents throughout the world who are undergoing peritoneal dialysis, the tissue sources of this water fl

278 oneal membrane could improve the practice of peritoneal dialysis through the production of proteins t

279 ble survival benefit of a timely change from peritoneal dialysis to hemodialysis.

280 We developed a strategy based on peritoneal dialysis to reduce blood glutamate levels, th

281 ialysis dose and the more efficacious use of peritoneal dialysis to treat patients with end-stage ren

282 ic or uremic patients and of those receiving peritoneal dialysis treatment have increased levels of t

283 mong ESRD patients receiving hemodialysis or peritoneal dialysis, two or more values of intact PTH (i

284 Whether differences in peritoneal dialysis use among children are due to the pe

285 tients receiving maintenance hemodialysis or peritoneal dialysis, using this definition, the prevalen

286 roke may actually be greater for patients on peritoneal dialysis versus hemodialysis in spite of thei

287 Cumulative survival probabilities for peritoneal dialysis versus hemodialysis were 85.8% versu

288 was used to compare the risk for death with peritoneal dialysis versus hemodialysis.

289 d-greater odds favoring death from stroke on peritoneal dialysis versus hemodialysis.

290 Treatment recommendations for peritoneal dialysis vs hemodialysis, compared based on n

291 ge was 70 years, and the mean time receiving peritoneal dialysis was 3 years.

292 Peritoneal dialysis was also carried out in a separate s

293 Peritoneal dialysis was associated with improved surviva

294 to normalize creatinine clearance (Ccr), in peritoneal dialysis was studied by: (1) mathematical com

295 Patients receiving peritoneal dialysis were much more likely than those rec

296 abetic renal failure patients on maintenance peritoneal dialysis were randomized to either a high or

297 Hemodialysis and peritoneal dialysis were the only forms of treatment ava

298 EM could reduce the range of indications for peritoneal dialysis, widen the range of indications for

299 uiring short- and long-term hemodialysis and peritoneal dialysis will allow appropriate planning for

300 thways for fluid and solute transport during peritoneal dialysis will permit improvements in the adeq